PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy (Syena/MD Anderson Cancer Center)

N/A

Report date: 2024/05/08 10:19:51
First In Class

Base Information

Drug NamePRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy (Syena/MD Anderson Cancer Center)
Drug Alias NamePRAME-TCR-NK cell therapy (Syena/MD Anderson Cancer Center)SY-307
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionNY-ESO-1 gene transferenceInterleukin-15 modulators
TargetsCancer/testis antigen 1Interleukin-15
Therapy Area/IndicationsBone Marrow Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaN/A
Originator CompaniesReplay Holdings LLCThe University Of Texas MD Anderson Cancer CenterSyena
China Registration ClassN/A

Develop Information

Active CompaniesReplay Holdings LLC
Inactive CompaniesN/A
Active IndicationsBone Marrow Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A